Danicopan Patent Expiration
Danicopan was first introduced by Alexion Pharmaceuticals Inc
Danicopan Patents
Given below is the list of patents protecting Danicopan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Voydeya | US12076319 | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria | Aug 02, 2038 | Alexion Pharms Inc |
| Voydeya | US9796741 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | Mar 29, 2038 | Alexion Pharms Inc |
Danicopan's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Danicopan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | Alexion Pharmaceuticals, Inc. | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |